Shorts

Dr Patel: Considerations for Adjuvant Cemiplimab in CSCC

Trial Opens Up More Avenues for Treatment in Patients with Bladder Cancer

A 13-Year-Old Drug’s Persisting Power in Prostate Cancer

Clinical Trial Achieves 60% Reduction in the Risk of Tumor Recurrence

Pembrolizumab and Enfortumab Vedotin Demonstrate Potential in Bladder Cancer Treatment

Delaying Progression in Nonmetastatic Prostate Cancer: Insights from EMBARK

Perioperative Pembrolizumab Doubles Survival in Metastatic Bladder Cancer

The Challenge of Treating High-Risk nmCSPC

Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer

Adverse Events to Watch for With Ribociclib

Dr Mayer Discusses PFS Data From evERA at ESMO 2025

How a New Drug is Changing Breast Cancer Treatment Forever

1 in 3 Breast Cancer Patients at High Risk

Why Understanding Tumor Biology is Key to Better Breast Cancer Care

FDA Requires 5 Years of Follow Up—Is It Too Much?

How Breast Cancer Treatment Became More Personalized & Effective

Reviewing the FDA Draft Guidance on Radiopharmaceuticals

Advantages of NK Cell Therapy

Understanding High-Risk Smoldering Multiple Myeloma

Looking Ahead From DeLLphi-303

Dr Petrylak: Unmet Needs in Prostate Cancer

Blood Cancer Awareness Month: Unmet Needs in Lymphoma

Dr Poh: Considerations for Tafasitamab

Vepdegestrant for ESR1-Mutant Breast Cancer: Safety and Tolerability

Funding Cancer Research

A New Hope: Fighting Ovarian Cancer at its Weakest

Talquetamab: The Perfect Bridge to CAR T?

The Race Against Time: Why CAR T-Cell Therapy Isn't a Quick Fix

Clinical Trial Limitations in MDS

Impactful Survival Data from the COMMANDS Trial of Luspatercept in Low-Risk MDS